Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Estimates By $0.06 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) posted its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06), Zacks reports.

Corvus Pharmaceuticals Trading Down 14.8 %

Shares of Corvus Pharmaceuticals stock opened at $3.35 on Thursday. The firm has a market capitalization of $215.26 million, a PE ratio of -3.60 and a beta of 0.91. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The business’s 50-day moving average price is $4.67 and its 200-day moving average price is $6.08.

Wall Street Analysts Forecast Growth

CRVS has been the topic of several recent research reports. Oppenheimer restated an “outperform” rating and set a $15.00 target price (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Corvus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $12.63.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.